Silence Therapeutics strengthens patent portfolio of RNAi therapeutics in solid tumor treatment

Silence Therapeutics plc (AIM: SLN) today announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance on a patent application directed to methods of treatment using a high-value therapeutic target in the area of oncology.  Known as PKN-3, the target is a protein kinase C-related molecule that is believed to play an important role in the growth of cancer cells, as well as metastasis formation.  The allowed subject matter is directed to, among other things, methods of treating cancer with small interfering RNA (siRNA) or antisense molecules that target the PKN-3 messenger RNA (mRNA). The claims cover the siRNA molecule in Silence's lead clinical compound, Atu027, an RNAi therapeutic which targets PKN-3 for the treatment of advanced solid tumors.

"This action by the USPTO is the latest step in Silence's establishment of a proprietary and compelling RNAi therapeutic franchise which includes PKN-3 for the treatment of cancer.  This development strengthens our dominant intellectual property position surrounding PKN-3, while specifically enhancing our global protection for Atu027, our Phase I candidate," said Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics. "At the same time, this milestone serves to supplement our already broad and diverse global RNAi intellectual property portfolio and enhances the significant proprietary position that this portfolio affords."

Silence has built a strong and diverse intellectual property portfolio covering all essential areas of RNAi therapeutic development including multiple proprietary siRNA delivery technologies, potent siRNA sequences and key siRNA sequence and chemical modifications, as well as specific high-value disease targets.  

SOURCE Silence Therapeutics plc


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Phase I/II LIBRETTO-001 trial: RET inhibitor achieves durable objective responses across multiple tumors